Vimarsana
Biggest News Aggregation in the World

Page 3 - Bertram Pitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bertram Pitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bertram Pitt Today - Breaking & Trending Today

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Call Transcript - Vimarsana News

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2022 Earnings Call Transcript

Operator: Good day, ladies and gentlemen. Welcome to the Lexicon Pharmaceuticals Inc. Third Quarter 2022 Earnings Conference Call. At this time all lines are in a listen-only mode.

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure - Vimarsana News

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin's Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge 

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript - Vimarsana News

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:NASDAQ:LXRX) Q3 2022 Earnings Conference Call November 09, 2022 5:00 PM ET Company Participants Mike Kelly – Investor Relations Lonnel Coats – Chief...

TRANSFORM-HF: Loop Diuretics Show No Difference in Mortality and Hospitalizations for Heart Failure - Vimarsana News

TRANSFORM-HF: Loop Diuretics Show No Difference in Mortality and Hospitalizations for Heart Failure

The results of the TRANSFORM-HF study, which explored the effects of two different therapies on heart failure outcomes, were featured during the first

Source: yale.edu
Two heart failure therapies prove to be nearly identical in reducing death - Vimarsana News

Two heart failure therapies prove to be nearly identical in reducing death

In a head-to-head comparison of two so-called 'water pills' that keep fluid from building up in patients with heart failure, the therapies proved nearly identical in reducing deaths, according to a large study led by Duke Health researchers.